American Society of Hematology

Figure 4

$Figure 4. HDAC6 has chaperone association with hsp90. (A) K562 cells or primary AML sample were treated with indicated doses of 17-AAG for 16 hours and 24 hours, respectively. After this, the resulting lysates were probed for HDAC6, acetyl-tubulin, and β-actin. (B) HDAC6 was immunoprecipitated from the cells incubated for 4 hours with indicated doses of 17-AAG and immunoblotted with anti-hsp90, anti-hsp70, or anti-HDAC6 antibody. (C) K562 cells were exposed to indicated concentrations of drugs for 8 hours and the resulting cell lysates were immunoblotted for HDAC6 and β-actin. (D) K562 cells were exposed to indicated concentration of drugs for 8 hours and NP-40–insoluble and –soluble fractions were prepared from the cell lysates. The resulting fractions were immunoblotted with anti-HDAC6 or anti–c-Raf antibodies.$

HDAC6 has chaperone association with hsp90. (A) K562 cells or primary AML sample were treated with indicated doses of 17-AAG for 16 hours and 24 hours, respectively. After this, the resulting lysates were probed for HDAC6, acetyl-tubulin, and β-actin. (B) HDAC6 was immunoprecipitated from the cells incubated for 4 hours with indicated doses of 17-AAG and immunoblotted with anti-hsp90, anti-hsp70, or anti-HDAC6 antibody. (C) K562 cells were exposed to indicated concentrations of drugs for 8 hours and the resulting cell lysates were immunoblotted for HDAC6 and β-actin. (D) K562 cells were exposed to indicated concentration of drugs for 8 hours and NP-40–insoluble and –soluble fractions were prepared from the cell lysates. The resulting fractions were immunoblotted with anti-HDAC6 or anti–c-Raf antibodies.

This Feature Is Available To Subscribers Only